[관가 모니터] 복지부, CSO 고수수료ㆍ재위탁 점검…중소제약 긴장

The South Korean government's crackdown on CSO commission structures and sub-contracting marks a significant shift toward transparency in pharmaceutical sales. This investigation, coupled with generic drug price cuts, forces small and mid-sized pharmaceutical companies to move away from high-commission models that risk illegal rebates. Ultimately, the industry faces a transition where manufacturers must take greater legal responsibility for the entire sales chain, including sub-contracted partners.